title: Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.
abstract: This study characterizes the pharmacokinetics of ertapenem, a carbapenem antibiotic, in critically ill adult subjects receiving continuous renal replacement therapy (CRRT). Eight critically ill patients with suspected/known Gram-negative infections receiving continuous venovenous hemodialysis (CVVHD) or continuous venovenous hemodiafiltration (CVVHDF) and ertapenem were enrolled. One gram of ertapenem was infused over 30 min. Predialyzer blood samples were drawn with the first dose of ertapenem from the hemodialysis tubing at time zero, 30 min, and 1, 2, 4, 8, 12, 18, and 24 h after the start of the ertapenem infusion. Effluent was collected at the same time points. Ertapenem total serum, unbound serum, and effluent concentrations from all eight subjects were used simultaneously to perform a population compartmental pharmacokinetic modeling procedure using NONMEM. Monte Carlo simulations were performed to evaluate the ability of several ertapenem dosing regimens (500 mg once daily, 750 mg once daily, 500 mg twice daily, and 1,000 mg once daily) to obtain effective unbound serum concentrations above 0.5, 1, and 2 μg/ml. For our simulated patients, all regimens produced unbound ertapenem concentrations above 2 μg/ml for 40% of the dosing interval for at least 96% of simulated patients. (This study has been registered at ClinicalTrials.gov under registration no. NCT00877370.).
authors: University of Connecticut School of Pharmacy, Storrs, Connecticut, USA.
authors: Rachel F
authors: RF
authors: Eyler
authors: A Mary
authors: AM
authors: Vilay
authors: Ahmed M
authors: AM
authors: Nader
authors: Michael
authors: M
authors: Heung
authors: Melissa
authors: M
authors: Pleva
authors: Kevin M
authors: KM
authors: Sowinski
authors: Daryl D
authors: DD
authors: DePestel
authors: Fritz
authors: F
authors: Sörgel
authors: Martina
authors: M
authors: Kinzig
authors: Bruce A
authors: BA
authors: Mueller
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016638:Critical Illness; D000077727:Ertapenem; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy; D006440:Hemofiltration; D006801:Humans; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D047090:beta-Lactams / Q000493:pharmacokinetics* / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D047090:beta-Lactams; D000077727:Ertapenem